BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, Calne R. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation. 1999;67:505-509. [PMID: 10071017 DOI: 10.1097/00007890-199902270-00002] [Cited by in Crossref: 162] [Cited by in F6Publishing: 139] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Kong Y, Wang D, Shang Y, Liang W, Ling X, Guo Z, He X. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One. 2011;6:e24387. [PMID: 21931704 DOI: 10.1371/journal.pone.0024387] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
2 Pleguezuelo M, Germani G, Burroughs AK. Liver Transplantation: Prevention and Treatment of Rejection. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 685-723. [DOI: 10.1002/9781444314403.ch42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Vivarelli M, Vetrone G, Zanello M, Barba GL, Cucchetti A, Lauro A, Grazi GL, Pinna AD. Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature. Transplant Int 2006;19:1022-5. [DOI: 10.1111/j.1432-2277.2006.00381.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
4 Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 2003;35:143S-150S. [PMID: 12742487 DOI: 10.1016/s0041-1345(03)00233-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
5 Neff GW, Montalbano M, Slapak-Green G, Berney T, Bejarano PA, Joshi A, Icardi M, Nery J, Seigo N, Levi D, Weppler D, Pappas P, Ruiz J, Schiff ER, Tzakis AG. A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl 2003;9:477-83. [PMID: 12740790 DOI: 10.1053/jlts.2003.50119] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
6 Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc. 2003;35:209S-216S. [PMID: 12742498 DOI: 10.1016/s0041-1345(03)00217-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
7 Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl. 2001;7:473-484. [PMID: 11443573 DOI: 10.1053/jlts.2001.24645] [Cited by in Crossref: 135] [Cited by in F6Publishing: 110] [Article Influence: 6.8] [Reference Citation Analysis]
8 Zarrinpar A, Busuttil RW. Immunomodulating options for liver transplant patients. Expert Rev Clin Immunol 2012;8:565-78; quiz 578. [PMID: 22992151 DOI: 10.1586/eci.12.47] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
9 Villanueva J, Boukhamseen A, Bhorade SM. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J Heart Lung Transplant 2005;24:421-5. [PMID: 15797743 DOI: 10.1016/j.healun.2004.01.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
10 Belkin D, Carucci JA. Mohs surgery for squamous cell carcinoma. Dermatol Clin 2011;29:161-74, vii. [PMID: 21421142 DOI: 10.1016/j.det.2011.02.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
11 Liao Z, She C, Ma L, Sun Z, Li P, Zhang X, Wang P, Li W. KDELR2 Promotes Glioblastoma Tumorigenesis Targeted by HIF1a via mTOR Signaling Pathway. Cell Mol Neurobiol 2019;39:1207-15. [PMID: 31342232 DOI: 10.1007/s10571-019-00715-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ingle GR, Sievers TM, Holt CD. Sirolimus: Continuing the Evolution of Transplant Immunosuppression. Ann Pharmacother 2000;34:1044-55. [DOI: 10.1345/aph.19380] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
13 Liu YX, Jin LM, Zhou L, Xie HY, Jiang GP, Chen H, Zheng SS. Sirolimus attenuates reduced-size liver ischemia-reperfusion injury but impairs liver regeneration in rats. Dig Dis Sci. 2010;55:2255-2262. [PMID: 19856103 DOI: 10.1007/s10620-009-1002-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
14 Toso C, Patel S, Asthana S, Kawahara T, Girgis S, Kneteman NN, Shapiro AM, Bigam DL. The impact of sirolimus on hepatocyte proliferation after living donor liver transplantation. Clin Transplant. 2010;24:695-700. [PMID: 20002466 DOI: 10.1111/j.1399-0012.2009.01159.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Molinari M, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010;23:155-168. [PMID: 19765266 DOI: 10.1111/j.1432-2277.2009.00969.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
16 Guilbeau JM. Delayed Wound Healing with Sirolimus after Liver Transplant. Ann Pharmacother 2002;36:1391-5. [DOI: 10.1345/aph.1a128] [Cited by in Crossref: 70] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
17 Munoz SJ, Rothstein KD, Reich D, Manzarbeitia C. Long-term care of the liver transplant recipient. Clin Liver Dis 2000;4:691-710. [PMID: 11232168 DOI: 10.1016/s1089-3261(05)70133-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol 2006;12:3114-8. [PMID: 16718799 DOI: 10.3748/wjg.v12.i19.3114] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
19 Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008;14:633-638. [PMID: 18324656 DOI: 10.1002/lt.21420] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 11.4] [Reference Citation Analysis]
20 Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56:23-46. [PMID: 16039869 DOI: 10.1016/j.critrevonc.2005.03.012] [Cited by in Crossref: 271] [Cited by in F6Publishing: 215] [Article Influence: 16.9] [Reference Citation Analysis]
21 Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, Genyk Y, Mateo R, Gagandeep S, Sher LS. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther. 2006;23:513-520. [PMID: 16441472 DOI: 10.1111/j.1365-2036.2006.02770.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
22 Ghosh J, Kapur R. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia. Exp Hematol. 2017;50:13-21. [PMID: 28342808 DOI: 10.1016/j.exphem.2017.02.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
23 O???grady JG. Corticosteroid-Free Strategies in Liver Transplantation: . Drugs 2006;66:1853-62. [DOI: 10.2165/00003495-200666140-00006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Cahill BC, Somerville KT, Crompton JA, Parker ST, O'Rourke MK, Stringham JC, Karwande SV. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003;22:169-76. [PMID: 12581765 DOI: 10.1016/s1053-2498(02)00550-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
25 Lewis E, Weiler M, Chaimovitz C, Douvdevani A. Interleukin-15 is the main mediator of lymphocyte proliferation in cultures mixed with human kidney tubular epithelial cells. Transplantation 2001;72:886-90. [PMID: 11571455 DOI: 10.1097/00007890-200109150-00025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
26 Watson CJ, Bradley JA. Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transplantation Reviews 2006;20:104-14. [DOI: 10.1016/j.trre.2006.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
27 Wietzke-Braun P, Braun F, Sattler B, Ramadori G, Ringe B. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol 2004;10:2213-7. [PMID: 15259068 DOI: 10.3748/wjg.v10.i15.2213] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
28 McDiarmid SV. Liver transplantation. The pediatric challenge. Clin Liver Dis 2000;4:879-927. [PMID: 11232362 DOI: 10.1016/s1089-3261(05)70146-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
29 Vivarelli M, Dazzi A, Cucchetti A, Gasbarrini A, Zanello M, Di Gioia P, Bianchi G, Tamè MR, Gaudio MD, Ravaioli M, Cescon M, Grazi GL, Pinna AD. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc 2010;42:2579-84. [PMID: 20832548 DOI: 10.1016/j.transproceed.2010.04.045] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
30 Choudhary NS, Saigal S, Shukla R, Kotecha H, Saraf N, Soin AS. Current status of immunosuppression in liver transplantation. J Clin Exp Hepatol 2013;3:150-8. [PMID: 25755489 DOI: 10.1016/j.jceh.2013.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
31 Orsini M, Morceau F, Dicato M, Diederich M. Autophagy as a pharmacological target in hematopoiesis and hematological disorders. Biochem Pharmacol 2018;152:347-61. [PMID: 29656115 DOI: 10.1016/j.bcp.2018.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Maluf DG, Mas VR, Archer KJ, Yanek K, King A, Ferreira-Gonzalez A, Fisher RA, Posner M. Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment. Transplantation. 2005;80:1705-1711. [PMID: 16378065 DOI: 10.1097/01.tp.0000187869.04180.7f] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
33 Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J Hepatol 2012;56:288-90. [PMID: 21741926 DOI: 10.1016/j.jhep.2011.06.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
34 Everson GT. Everolimus and mTOR inhibitors in liver transplantation: Opening the “box”. Liver Transpl 2006;12:1571-3. [DOI: 10.1002/lt.20845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
35 Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10:1301-11. [PMID: 15376305 DOI: 10.1002/lt.20237] [Cited by in Crossref: 194] [Cited by in F6Publishing: 170] [Article Influence: 12.1] [Reference Citation Analysis]
36 Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, Levy MF, Chinnakotla S, Dawson S, Randall HB. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc. 2005;37:4416-4423. [PMID: 16387135 DOI: 10.1016/j.transproceed.2005.10.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
37 Chinnakotla S, Klintmalm GB. Induction and Maintenance of Immunosuppression. Transplantation of the Liver. Elsevier; 2005. pp. 1213-34. [DOI: 10.1016/b978-0-7216-0118-2.50080-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
38 Kostakis I, Sotiropoulos G, Kouraklis G. Pneumocystis jirovecii Pneumonia in Liver Transplant Recipients: A Systematic Review. Transplantation Proceedings 2014;46:3206-8. [DOI: 10.1016/j.transproceed.2014.09.156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
39 Myckatyn TM, Ellis RA, Grand AG, Sen SK, Lowe JB, Hunter DA, Mackinnon SE. The Effects of Rapamycin in Murine Peripheral Nerve Isografts and Allografts: . Plastic and Reconstructive Surgery 2002;109:2405-17. [DOI: 10.1097/00006534-200206000-00035] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
40 Lam P, Yoshida A, Brown K, Abouljoud M, Bajjoka I, Dagher F, Moonka DK. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci. 2004;49:1029-1035. [PMID: 15309896 DOI: 10.1023/b:ddas.0000034567.53748.df] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
41 Jiang YP, Ballou LM, Lin RZ. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J Biol Chem. 2001;276:10943-10951. [PMID: 11278364 DOI: 10.1074/jbc.m007758200] [Cited by in Crossref: 66] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
42 Calmus Y, Durrbach A. Everolimus de novo in liver transplantation. Gastroenterol Clin Biol. 2009;33 Suppl 4:S247-S252. [PMID: 20004330 DOI: 10.1016/s0399-8320(09)73161-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
43 Basso M, Subramaniam P, Tredger M, Verma A, Heaton N, Rela M, Mieli-vergani G, Dhawan A. Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients: Sirolimus in pediatric liver transplantation. Pediatric Transplantation 2011;15:722-7. [DOI: 10.1111/j.1399-3046.2011.01560.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
44 Capone D, Gentile A, Polichetti G, Federico S, Sabbatini M, Acampora A, Basile V, Pieri M, Tarantino G. Stability of Sirolimus and Everolimus Measured by Immunoassay Techniques in Whole Blood Samples from Kidney Transplant Patients. Int J Immunopathol Pharmacol 2008;21:297-307. [DOI: 10.1177/039463200802100206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
45 Gibelli NE, Tannuri U, Pinho-Apezzato ML, Tannuri AC, Maksoud-Filho JG, Andrade WC, Velhote MC, Santos MM, Ayoub AA, Marques da Silva M. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant Proc 2009;41:901-3. [PMID: 19376384 DOI: 10.1016/j.transproceed.2009.01.054] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
46 Haugen CE, Holscher CM, Garonzik-Wang J, Pozo M, Warsame F, McAdams-DeMarco M, Segev DL. National Trends in Liver Transplantation in Older Adults. J Am Geriatr Soc 2018;66:2321-6. [PMID: 30325004 DOI: 10.1111/jgs.15583] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
47 Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P. Minimization of steroids in liver transplantation. Transpl Int 2009;22:2-19. [PMID: 19121145 DOI: 10.1111/j.1432-2277.2008.00758.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
48 Avitzur Y, Jimenez-rivera C, Fecteau A, Jones N, Ngan BY, Ng VL. Interstitial Granulomatous Pneumonitis associated with Sirolimus in a Child after Liver Transplantation: . Journal of Pediatric Gastroenterology and Nutrition 2003;37:91-4. [DOI: 10.1097/00005176-200307000-00017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
49 Brown GR, Bamford AM, Bowyer J, James DS, Rankine N, Tang E, Torr V, Culbert EJ. Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorganic & Medicinal Chemistry Letters 2000;10:575-9. [DOI: 10.1016/s0960-894x(00)00051-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
50 Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant. 2009;2009:701464. [PMID: 20130772 DOI: 10.1155/2009/701464] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
51 Sacks SH. Rapamycin on trial. Nephrology Dialysis Transplantation 1999;14:2087-9. [DOI: 10.1093/ndt/14.9.2087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
52 Schaffellner S, Jakoby E, Kniepeiss D, Stadlbauer V, Duller D, Iberer F, Tscheliessnigg K. Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. International Immunopharmacology 2005;5:137-40. [DOI: 10.1016/j.intimp.2004.09.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
53 Sharpe LJ, Brown AJ. Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochemical and Biophysical Research Communications 2008;373:670-4. [DOI: 10.1016/j.bbrc.2008.06.108] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
54 Pridöhl O, Heinemann K, Hartwig T, Witzigmann H, Lamesch P, Fangmann J, Berr F, Hauss J, Kohlhaw K. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. Transplant Proc 2001;33:3229-31. [PMID: 11750384 DOI: 10.1016/s0041-1345(01)02373-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
55 Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl. 2001;7:401-408. [PMID: 11349259 DOI: 10.1053/jlts.2001.23916] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
56 Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35:193S-200S. [PMID: 12742496 DOI: 10.1016/S0041-1345(03)00234-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 15] [Article Influence: 5.1] [Reference Citation Analysis]
57 Aspeslet LJ, Yatscoff RW. Requirements for therapeutic Drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clinical Therapeutics 2000;22:B86-92. [DOI: 10.1016/s0149-2918(00)89025-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
58 Scherer MN, Banas B, Mantouvalou K, Schnitzbauer A, Obed A, Krämer BK, Schlitt HJ. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg 2007;392:511-23. [DOI: 10.1007/s00423-007-0188-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
59 Kurtovic J, Riordan SM, Williams R. Liver transplantation for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:147-160. [PMID: 15757810 DOI: 10.1016/j.bpg.2004.10.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
60 Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43:1170-1180. [PMID: 12177161 DOI: 10.1194/jlr.m100392-jlr200] [Cited by in Crossref: 210] [Article Influence: 11.7] [Reference Citation Analysis]
61 Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. Journal of Hepatology 2003;39:664-78. [DOI: 10.1016/s0168-8278(03)00428-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
62 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
63 Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R. Experience with the use of sirolimus in liver transplantation—use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000;6:734-40. [DOI: 10.1053/jlts.2000.19023] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 3.0] [Reference Citation Analysis]
64 Cohen SM. Current immunosuppression in liver transplantation. Am J Ther 2002;9:119-25. [PMID: 11897926 DOI: 10.1097/00045391-200203000-00006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
65 Klintmalm GB, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant. 2014;2014:845438. [PMID: 24719752 DOI: 10.1155/2014/845438] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
66 Sanchez Antolín G, Garcia Pajares F, Lorenzo Pelayo S, Herranz Bachiller MT, Almohalla C, Velicia R, Caro Paton A. Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. Transplant Proc. 2011;43:714-717. [PMID: 21486581 DOI: 10.1016/j.transproceed.2011.01.105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
67 Olson JC, Wiesner RH. Immunomodulating therapy in liver transplantation: principles and practice. Immunotherapy 2012;4:793-805. [PMID: 22947008 DOI: 10.2217/imt.12.69] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
68 Nishida S, Pinna A, Verzaro R, Levi D, Kato T, Khan F, Nery J, Weppler D, Tzakis A. Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation. Transplantation Proceedings 2001;33:1495. [DOI: 10.1016/s0041-1345(00)02566-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
69 Brown KA, Moonka DK. Liver transplantation. Curr Opin Gastroenterol. 2001;17:299-303. [PMID: 17031172 DOI: 10.1097/00001574-200105000-00014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg K. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 2004;18:642-6. [DOI: 10.1111/j.1399-0012.2004.00253.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
71 Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001;23:559-86. [PMID: 11591905 DOI: 10.1097/00007691-200110000-00012] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 4.4] [Reference Citation Analysis]
72 Brewer JD, Otley CC, Christenson LJ, Phillips PK, Roenigk RK, Weaver AL. The Effects of Sirolimus on Wound Healing in Dermatologic Surgery: . Dermatologic Surgery 2008;34:216-23. [DOI: 10.1097/00042728-200802000-00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
73 Spada M, Riva S, Maggiore G, Cintorino D, Gridelli B. Pediatric liver transplantation. World J Gastroenterol. 2009;15:648-674. [PMID: 19222089 DOI: 10.3748/wjg.15.648] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
74 Witzigmann H, Rhein T, Geissler F, Thiery J, Serr F, Tannapfel A, Uhlmann D, Metzner R, Hauss J. Immunosuppression with sirolimus/tacrolimus combination in pancreas transplantation: 1-year results. Transplantation Proceedings 2002;34:3354-6. [DOI: 10.1016/s0041-1345(02)03675-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Hu AB, Wu LW, Tai Q, Zhu XF, He XS. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center: Steroid-minimization in LT. Journal of Digestive Diseases 2013;14:38-44. [DOI: 10.1111/1751-2980.12008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
76 Wall WJ. Hepatocellular cancer, transplantation, and sirolimus. Liver Transpl 2004;10:1312-4. [DOI: 10.1002/lt.20283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
77 Hafizi S, Mordi VN, Andersson KM, Chester AH, Yacoub MH. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. Vascular Pharmacology 2004;41:167-76. [DOI: 10.1016/j.vph.2004.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
78 Sevmis S, Karakayali H, Emiroglu R, Akkoc H, Haberal M. Tacrolimus-Related Seizure in the Early Postoperative Period After Liver Transplantation. Transplantation Proceedings 2007;39:1211-3. [DOI: 10.1016/j.transproceed.2007.02.049] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
79 Pieri M, Capone D, Gentile A, Miraglia N, Leo E, Federico S, Basile V, Acampora A. Immunoassay determination of rapamycin: reliability of the method with respect to liquid chromatography mass spectrometric quantification. Clin Transplant 2007;21:633-7. [DOI: 10.1111/j.1399-0012.2007.00701.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
80 Macdonald AS. Use of mTOR inhibitors in human organ transplantation. Expert Review of Clinical Immunology 2014;3:423-36. [DOI: 10.1586/1744666x.3.3.423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
81 Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl. 2005;11:267-280. [PMID: 15719409 DOI: 10.1002/lt.20373] [Cited by in Crossref: 70] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
82 Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother 2007;8:1275-82. [PMID: 17563262 DOI: 10.1517/14656566.8.9.1275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
83 Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, Begliomini B, Di Benedetto F, Gerunda GE. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10:2252-2262. [PMID: 20486905 DOI: 10.1111/j.1600-6143.2010.03128.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 89] [Article Influence: 9.4] [Reference Citation Analysis]
84 Fung J. Rapamycin: Friend, foe, or misunderstood? Liver Transplantation 2003;9:469-72. [DOI: 10.1053/jlts.2003.50101] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
85 Ryskalin L, Limanaqi F, Frati A, Busceti CL, Fornai F. mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders. Int J Mol Sci 2018;19:E2226. [PMID: 30061532 DOI: 10.3390/ijms19082226] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 15.7] [Reference Citation Analysis]
86 Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425-4431. [PMID: 18776081 DOI: 10.1182/blood-2008-07-169342] [Cited by in Crossref: 111] [Cited by in F6Publishing: 86] [Article Influence: 8.5] [Reference Citation Analysis]
87 Neuberger J. Liver transplantation. J Hepatol 2000;32:198-207. [PMID: 10728805 DOI: 10.1016/s0168-8278(00)80426-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
88 Lerut JP. Avoiding steroids in solid organ transplantation. Transplant Int 2003;16:213-24. [DOI: 10.1111/j.1432-2277.2003.tb00291.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
89 Haydon GH, Neuberger J. Liver transplantation of patients in end-stage cirrhosis. Best Practice & Research Clinical Gastroenterology 2000;14:1049-73. [DOI: 10.1053/bega.2000.0146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
90 Levy G. Neoral use in the liver transplant recipient. Transplantation Proceedings 2000;32:S2-9. [DOI: 10.1016/s0041-1345(00)00859-9] [Cited by in Crossref: 11] [Article Influence: 0.5] [Reference Citation Analysis]
91 Kahan BD, Camardo JS. RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1: . Transplantation 2001;72:1181-93. [DOI: 10.1097/00007890-200110150-00001] [Cited by in Crossref: 181] [Cited by in F6Publishing: 147] [Article Influence: 9.1] [Reference Citation Analysis]
92 Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol. 2009;15:4225-4233. [PMID: 19750565 DOI: 10.3748/wjg.15.4225] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
93 Zucker M, Baran D, Arroyo L, Goldstein D, Neacy C, Mele L, Weinberg A, Prendergast T, Ribner H. De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow-Up Analysis. Transplantation Proceedings 2005;37:2231-9. [DOI: 10.1016/j.transproceed.2005.03.086] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
94 Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 2003;9:463-468. [PMID: 12740787 DOI: 10.1053/jlts.2003.50079] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
95 Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001;7:343-51. [PMID: 11303295 DOI: 10.1053/jlts.2001.23012] [Cited by in Crossref: 89] [Cited by in F6Publishing: 75] [Article Influence: 4.5] [Reference Citation Analysis]
96 Mcdiarmid S. Management of the pediatric liver transplant patient. Liver Transplantation 2001;7:S77-86. [DOI: 10.1053/jlts.2001.28643] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
97 Maheshwari A, Torbenson MS, Thuluvath PJ. Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Dig Dis Sci. 2006;51:1677-1684. [PMID: 16964550 DOI: 10.1007/s10620-005-9026-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
98 Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006;20 Suppl 17:30-43. [PMID: 17100699 DOI: 10.1111/j.1399-0012.2006.00598.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
99 Neff GW, Montalbano M, Slapak-Green G, Meyer D, Berney T, Safdar K, Schiff ER, Tzakis AG. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc. 2003;35:3029-3031. [PMID: 14697970 DOI: 10.1016/j.transproceed.2003.10.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
100 Pieri M, Miraglia N, Castiglia L, Genovese G, Basilicata P, Simonelli A, Acampora A. Determination of rapamycin: quantification of the sodiated species by an ion trap mass spectrometer as an alternative to the ammoniated complex analysis by triple quadrupole. Rapid Commun Mass Spectrom 2005;19:3042-50. [DOI: 10.1002/rcm.2168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
101 Pietra BA, Boucek MM. Immunosuppression for pediatric cardiac transplantation in the modern era. Prog Pediatr Cardiol 2000;11:115-29. [PMID: 10856693 DOI: 10.1016/s1058-9813(00)00043-6] [Cited by in Crossref: 17] [Article Influence: 0.8] [Reference Citation Analysis]
102 Tan H, Schiano TD. Effects of Liver Disease on Drug Metabolism in Humans. Encyclopedia of Drug Metabolism and Interactions. Hoboken: John Wiley & Sons, Inc.; 2011. [DOI: 10.1002/9780470921920.edm125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Montalbano M, Neff GW, Slapak-Green G, Berney T, Meyer D. Sirolimus therapy in orthotopic liver transplant (OLT) recipients with acute renal insufficiency. Dig Dis Sci 2004;49:1986-9. [PMID: 15628739 DOI: 10.1007/s10620-004-9606-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
104 Mehrabi A, Fonouni H, Wente M, Sadeghi M, Eisenbach C, Encke J, Schmied BM, Libicher M, Zeier M, Weitz J. Wound complications following kidney and liver transplantation. Clin Transplant. 2006;20 Suppl 17:97-110. [PMID: 17100709 DOI: 10.1111/j.1399-0012.2006.00608.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 82] [Article Influence: 8.2] [Reference Citation Analysis]
105 Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, Krom RA. Recent advances in liver transplantation. Mayo Clin Proc. 2003;78:197-210. [PMID: 12583530 DOI: 10.4065/78.2.197] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
106 Hale DA, Gottschalk R, Umemura A, Maki T, Monaco AP. Establishment of stable multilineage hematopoietic chimerism and donor-specific tolerance without irradiation. Transplantation 2000;69:1242-51. [PMID: 10798737 DOI: 10.1097/00007890-200004150-00008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 2.6] [Reference Citation Analysis]
107 Lee KW, Seo YD, Oh SC, Suh SW, Jeong J, Kim H, Yi NJ, Suh KS. What is the best immunosuppressant combination in terms of antitumor effect in hepatocellular carcinoma? Hepatol Res 2016;46:593-600. [PMID: 26348114 DOI: 10.1111/hepr.12588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
108 Vilatoba M, Contreras JL, Eckhoff DE. New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity: . Current Opinion in Organ Transplantation 2003;8:139-45. [DOI: 10.1097/00075200-200306000-00002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
109 Cronin DC, Faust TW, Brady L, Conjeevaram H, Jain S, Gupta P, Millis JM. MODERN IMMUNOSUPPRESSION. Clinics in Liver Disease 2000;4:619-55. [DOI: 10.1016/s1089-3261(05)70130-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
110 Di Benedetto F, Di Sandro S, De Ruvo N, Masetti M, Montalti R, Romano A, Guerrini GP, Ballarin R, De Blasiis MG, Gerunda GE. Sirolimus monotherapy in liver transplantation. Transplant Proc 2007;39:1930-2. [PMID: 17692656 DOI: 10.1016/j.transproceed.2007.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
111 Iglesias J, Ortega J, Lopez JA, Sanchez L, Allende E, Asensio M, Margarit C. Rapamycin-based rescue therapy after chronic rejection in a pediatric liver transplant patient. Transplant Int 2003;16:765-7. [DOI: 10.1111/j.1432-2277.2003.tb00238.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
112 Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2005;44:769-786. [PMID: 16029064 DOI: 10.2165/00003088-200544080-00001] [Cited by in Crossref: 75] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
113 Raimondo ML, Burroughs AK. Single-Agent Immunosuppression After Liver Transplantation: What is Possible? Drugs 2002;62:1587-97. [DOI: 10.2165/00003495-200262110-00002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
114 Bauer A, Brönstrup M. Industrial natural product chemistry for drug discovery and development. Nat Prod Rep 2014;31:35-60. [DOI: 10.1039/c3np70058e] [Cited by in Crossref: 140] [Cited by in F6Publishing: 26] [Article Influence: 20.0] [Reference Citation Analysis]
115 Shah M, Shankar A, Gee I, Nash K, Hoare M, Gibbs P, Davies S, Alexander GJM. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients. Aliment Pharmacol Ther 2015;41:379-92. [DOI: 10.1111/apt.13049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
116 Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12:1640-1648. [PMID: 16598777 DOI: 10.1002/lt.20707] [Cited by in Crossref: 105] [Cited by in F6Publishing: 82] [Article Influence: 7.5] [Reference Citation Analysis]
117 Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009;9:247-261. [PMID: 19192962 DOI: 10.1586/14737140.9.2.247] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
118 Preston E, Kirk AD. Context-based therapy: A conceptual framework for transplantation tolerance. Transplantation Reviews 2002;16:142-62. [DOI: 10.1053/trre.2002.126011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
119 Tran TT, Nissen N, Poordad FF, Martin P. Advances in liver transplantation. New strategies and current care expand access, enhance survival. Postgrad Med 2004;115:73-6, 79-85. [PMID: 15171080 DOI: 10.3810/pgm.2004.05.1514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
120 Watson CJ. Sirolimus (rapamycin) in clinical transplantation. Transplantation Reviews 2001;15:165-77. [DOI: 10.1016/s0955-470x(01)80016-1] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
121 Firpi RJ, Tran TT, Flores P, Nissen N, Colquhoun S, Shackleton C, Martin P, Vierling JM, Poordad FF. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther. 2004;19:1033-1039. [PMID: 15113371 DOI: 10.1111/j.1365-2036.2004.01923.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
122 Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnigg K. Sirolimus and mycophenolate mofetil after liver transplantation. Transplant Int 2003;16:504-9. [DOI: 10.1111/j.1432-2277.2003.tb00339.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
123 Liu LU, Schiano TD. Long-term care of the liver transplant recipient. Clin Liver Dis. 2007;11:397-416. [PMID: 17606214 DOI: 10.1016/j.cld.2007.04.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
124 McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000;355:376-377. [PMID: 10665560 DOI: 10.1016/s0140-6736(99)03882-9] [Cited by in Crossref: 252] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
125 Tracey C, Hawley C, Griffin AD, Strutton G, Lynch S. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl 2005;11:987-9. [DOI: 10.1002/lt.20499] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
126 Best J. Trends in expenditures for Medicare liver transplant recipients. Liver Transplantation 2001;7:858-62. [DOI: 10.1053/jlts.2001.27868] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
127 Heffron TG, Smallwood GA, Davis L, Martinez E, Stieber AC. Sirolimus-based immunosuppressive [correction of immunosuppresive] protocol for calcineurin sparing in liver transplantation. Transplant Proc 2002;34:1522-3. [PMID: 12176466 DOI: 10.1016/s0041-1345(02)02956-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
128 Al-hussaini A, Tredger JM, Dhawan A. Immunosuppression in Pediatric Liver and Intestinal Transplantation: A Closer Look at the Arsenal: . Journal of Pediatric Gastroenterology and Nutrition 2005;41:152-65. [DOI: 10.1097/01.mpg.0000172260.46986.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
129 Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology. 2001;120:749-762. [PMID: 11179248 DOI: 10.1053/gast.2001.22583] [Cited by in Crossref: 166] [Cited by in F6Publishing: 133] [Article Influence: 8.3] [Reference Citation Analysis]
130 Fisher A, Seguel JM, de la Torre AN, Wilson D, Merchant A, Arora RK, Koneru B. Effect of sirolimus on infection incidence in liver transplant recipients: Sirolimus in Liver Transplantation. Liver Transpl 2004;10:193-8. [DOI: 10.1002/lt.20072] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
131 Ringe B, Braun F, Schütz E, Füzesi L, Lorf T, Canelo R, Oellerich M, Ramadori G. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation. 2001;71:508-515. [PMID: 11258429 DOI: 10.1097/00007890-200102270-00005] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
132 Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: what role in liver transplantation? J Hepatol. 2011;55:1441-1451. [PMID: 21781947 DOI: 10.1016/j.jhep.2011.06.015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
133 Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003;9:1079-1085. [PMID: 14526403 DOI: 10.1053/jlts.2003.50183] [Cited by in Crossref: 106] [Cited by in F6Publishing: 90] [Article Influence: 6.2] [Reference Citation Analysis]
134 Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation 2011;91:128-32. [PMID: 21452417 DOI: 10.1097/tp.0b013e3181fe131b] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
135 Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, Jain A, Reyes J. Long term management of liver transplant rejection in children. BioDrugs 2000;14:31-48. [PMID: 18034554 DOI: 10.2165/00063030-200014010-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
136 Moser MA. Options for Induction Immunosuppression in Liver Transplant Recipients: . Drugs 2002;62:995-1011. [DOI: 10.2165/00003495-200262070-00002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
137 Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Shiffman ML, Posner MP. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002;16 Suppl 7:49-51. [PMID: 12372044 DOI: 10.1034/j.1399-0012.16.s7.7.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
138 Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E. Cancer wars: natural products strike back. Front Chem. 2014;2:20. [PMID: 24822174 DOI: 10.3389/fchem.2014.00020] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
139 Forgacs B, Merhav HJ, Lappin J, Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 2005;37:1912-4. [PMID: 15919502 DOI: 10.1016/j.transproceed.2005.02.101] [Cited by in Crossref: 53] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]